Biorain Biological Tumor Early Screening Solution: Comprehensive Assistance for Integrated Cancer Prevention and Control

April 15-21, 2023 is the 29th National Cancer Prevention and Control Awareness Week. The theme of this year's Awareness Week is“Comprehensive Action on Cancer Prevention and Control - Whole Population, Whole Cycle, and Whole Society”。

Cancer is a general term for a large category of diseases, with over 3.5 million new cancer cases and over 2 million deaths occurring annually in China. The situation of prevention and control is severe. The most common cancers in China include lung cancer, breast cancer, stomach cancer, liver cancer, cervical cancer, thyroid cancer, etc. The carcinogenic factors are very complex, including chemical, physical, chronic infection and other external factors as well as genetic, immune, age, lifestyle and other self factors.

The occurrence of cancer is a long-term, chronic, and multi-stage process. It usually takes 10 to 20 years, or even longer, for normal cells to evolve into cancer cells and then form tumors that endanger human health. The World Health Organization proposes that one-third of cancers can be completely prevented; One-third of cancers can be cured through early detection; One-third of cancers can be treated with existing medical measures to extend life, alleviate pain, and improve quality of life.

Taking effective measures to avoid or eliminate various carcinogenic factors on the human body and prevent cancer from occurring is the most thorough and ideal cancer prevention method. To prevent the occurrence of tumors, one can remember the four key words: reasonable diet, moderate exercise, smoking and alcohol restriction, balanced mindset, sufficient sleep, and regular physical examinations.

The core is regular and regular physical examinations. Especially for high-risk populations, conducting physical examinations can prevent the disease from developing in a more serious direction. Biorain Biological's fully automated integrated digital PCR can achieve technologies such as early screening of tumors, accompanying diagnosis, and prognosis monitoring. It has high sensitivity and quantitative analysis, achieving dynamic monitoring and providing timely genetic information for tumor diagnosis and recurrence. Discovering precancerous lesions and intervening before actual onset is an ideal goal for secondary prevention.
 

Standardizing treatment for cancer patients, striving to improve survival and tumor control rates, reducing complications and side effects, alleviating pain caused by cancer, and improving patient quality of life is a broad extension of the concept of prevention. The key point lies in standardized diagnosis and treatment, which means that every step involved in cancer diagnosis and treatment should be standardized to ensure that the treatment methods and processes are correct, advanced, and authoritative.

Biorain Biotechnology has launched solutions such as "Human BCR-ABL IS Detection Kit", "Human EGFR Gene Detection Kit", "Human HRE2 Gene Mutation Detection Kit", "Human Spein9, SDC2, SFRP2 Methylation Detection Kit" based on the company's independently developed integrated digital PCR platform in tumor prevention, diagnosis, treatment, and monitoring.

Biorain Biotechnology utilizes the advantages of absolute quantification, high precision, and high sensitivity of digital PCR to solve the pain points of traditional RT-PCR, achieving highly sensitive detection of BCR-ABL fusion genes. The linear detection range of BCR-ABL is 0.002%~50%, providing more sensitive and accurate BCR-ABL detection for chronic myeloid disease patients.

This product is applicable to the amplification level of human HER2 gene in peripheral blood or tissue samples of breast cancer patients, and the test results are used in combination with relevant clinical diagnosis and treatment specifications. It can be used for concomitant diagnosis of anti HER2 treatment in breast cancer patients and dynamic monitoring in the process of anti HER2 treatment, and is applicable to the population including those who need HER2 gene detection.

The kit detects methylation at three gene loci, combined with the accuracy of digital PCR quantification. The preliminary verification results are good, and it can provide a new solution for early screening of colorectal cancer tumors.

"Early" means opportunity and life. For the sake of our common health, please join in the early prevention and screening of common high incidence cancers and high-risk populations, spread scientific and effective concepts of cancer prevention and treatment, eliminate misconceptions about cancer, cultivate a healthy lifestyle, and comprehensively improve the level of early diagnosis and treatment of cancer in China. Biorain Biological's digital PCR solution is an ideal tool for cancer research, Comprehensive support for integrated cancer prevention and control!